Document |
Document Title |
WO/1998/011075A1 |
Corticotropin releasing factor (CRF) antagonists of Formula (I), and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorders, supranucle...
|
WO/1998/009949A1 |
Novel acetamide derivatives having a substituted heterocycle and consecutive dicarbonyl structures represented by chemical formula (I), for example, 1-pyrimidinylacetamide compounds, 1-pyrazinylacetamide compounds and 1-triazinylacetamid...
|
WO/1998/004247A1 |
The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds...
|
WO/1998/004247A2 |
The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds...
|
WO/1998/004913A1 |
Pharmacophore models of VLA-4 inhibitors, methods of identifying novel inhibitors and novel inhibitors identified by these methods.
|
WO/1998/002422A1 |
New substituted aromatic carbonyl compounds and their derivatives have the general formula (I), in which Q stands for oxygen, sulphur or imino (NH); R?1� stands for hydrogen or halogen; and R?2� stands for the group -A?1�-A?2�-A?...
|
WO/1998/000408A1 |
Compounds of the formula (I), in which -A- is a group (A�1?), (A�2?) or (A�3?) where the bonding of -A- to the nitrogen atom takes place via the carbon atom; R�1? is halogen, C�1?-C�4?alkyl, C�1?-C�4?haloalkyl, C�1?-Cï¿...
|
WO/1997/044324A1 |
The present invention provides novel compounds of formulae (I-VIII) for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) and a new use of known compounds IX to X for this purpose.
|
WO/1997/043238A1 |
The present invention provides pharmaceutical compositions and methods for treating certain conditions comprising administering an amount of a compound or composition of the invention which is effective to inhibit the activity of at leas...
|
WO/1997/043237A1 |
Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have generalized formula (I) wherein R1 repr...
|
WO/1997/043239A1 |
Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have generalized formula (1) wherein r is 0-2, T is sel...
|
WO/1997/035849A1 |
The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises a substituted 1,2,4-triazine of formula (I) and the biologically...
|
WO/1997/030980A1 |
The invention relates to novel substituted 2-aryl-1,2,4-triazine-3,5-di(thi)ones of the general formula (I) in which R1, R2, R3, R4, R5, Q1 and Q2 have the meanings given in the description, process for their production and their use as ...
|
WO/1997/026240A1 |
Novel compounds are provided which are inhibitors of MTP and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases, and have the structure (I) or (IA) or (IB) including pharmaceutically acceptable sa...
|
WO/1997/021685A1 |
A compound of formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
|
WO/1997/021683A1 |
Inhibitors of HIV protease are provided. When bound to HIV protease, the inhibitors are characterized by a unique three-dimensional conformation and orientation relative to the S1, S1', S2, S2', S3, and S3' subsites of the protease. Phar...
|
WO/1997/020828A1 |
Process of producing 3-amino-1,2,4-benzotriazine 1,4-dioxide by reacting benzofurazan-1 oxide with disodiumcyanamide under homogeneous conditions followed by allowing crystallization to occur in a buffered solution. In a preferred embodi...
|
WO/1997/020827A1 |
Novel fluorophenyl-triazine and pyrimidine derivatives of general formula (I), wherein R1 is an amino group, a 1-piperazinyl group or a 4-alkylpiperazin-1-yl group, where the alkyl group is a C1-4 chain, preferably methyl; each of R2, R3...
|
WO/1997/002244A1 |
Heterocyclic carboxylic acid derivatives represented by general formula (I) or physiologically acceptable salts thereof: wherein A is a heteroaryl group which has at least one nitrogen atom and may be substituted, or the like; B is heter...
|
WO/1997/000856A1 |
Carboxylic acid amide derivatives having formula (I) are disclosed, as well as several processes for preparing the same and their use as fungicides. In formula (I), Ar stands for optionally substituted arylene or heteroarylene; E stands ...
|
WO/1996/035669A1 |
Described are (het)aryloxy-, -thio-, aminocrotonates of formula (I) in which the substituents are defined as follows: U is oxygen, sulphur or amino; V is oxygen, sulphur, amino or alkylamino; X, Y, Z, independently of each other, are =N-...
|
WO/1996/022285A1 |
1,2,4-Triazine derivatives represented by general formula (1) and having excellent effects as an efficacious active ingredient of a herbicide and a process for producing the same, wherein X1 represents halogeno; X2 represents halogeno; X...
|
WO/1996/020935A1 |
Lamotrigine, 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, may be prepared by treating 6-(2,3-dichlorophenyl)-5-chloro-3-thiomethyl-1,2,4-triazine of formula (II) with ammonia. Percursors to the compound of formula (II), and their p...
|
WO/1996/020934A1 |
The invention provides a process for producing lamotrigine of formula (I) which process comprises subjecting a compound of formula (II), wherein R is CN or CONH2, in an organic solvent, to ultraviolet or visible radiation and, when R is ...
|
WO/1996/016949A1 |
Novel 3,5-dioxo-(2H,4H-triazine derivatives of general formula (I): wherein R1 is hydrogen, a C1-C4 alkyl radical, phenyl C1-C4 alkyl or phenyl, the phenyl ring being optionally substituted by one or more groupings such as (C1-C3) alkyl,...
|
WO/1996/015092A1 |
Fluorine-containing liquid crystal compounds comprise a fluorocarbon terminal portion having at least one catenary ether oxygen and a hydrocarbon terminal portion, the terminal portions being connected by a central core. The compounds ha...
|
WO/1995/030661A1 |
The invention relates to novel substituted aromatic thiocarboxylic acid amides of general formula (I) in which R1, R2 and R3 are hydrogen or various substituents and Z is possibly substituted monocyclic or bicyclic, saturated or unsatura...
|
WO/1995/026957A1 |
The invention concerns pharmaceutically useful compounds of formula (I), wherein Q is a naphthyl or biphenyl group; W, X, Y and Z are independently selected from nitrogen and CR2 such that two or three of W, X, Y and Z are nitrogen and t...
|
WO/1995/024403A1 |
A compound of formula (I), or a salt thereof, wherein n is 0, 1 or 2; and R is a group of formulae (II) to (XXI), wherein: the S(O)nCH2CH2CH=CF2 group is at least one of R1 (when attached to a carbon atom), R2, R3, R4, R5 or R6; R1 (when...
|
WO/1995/022523A1 |
A cyclic nitrogenous compound represented by general formula (1) and a herbicide containing the same, exhibiting a high herbicidal activity in a small dose, and having crop selectivity: wherein R1 represents alkyl; R represents hydgrogen...
|
WO/1995/018116A1 |
Arthropodicidal compounds, compositions and use of compounds having formula (I) wherein A, E, X, Y, Z, R1, R2, R3, R4, R5, n and m are as defined in the text.
|
WO/1995/018123A1 |
Compounds of formula (I) wherein n and Z are as defined in claim 1, and, where appropriate, tautomers thereof, in each case in free form, or in salt form, can be used as agrochemical active ingredients and can be prepared in a manner kno...
|
WO/1995/009842A1 |
The invention relates to heterocyclic carbamates of formula (I) in which X denotes a nitrogen atom or the group CR4 and Y denotes a nitrogen atom or the group CR5, where R2 and R3 independently of one another stand for radicals of the fo...
|
WO/1995/004045A1 |
This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production of physiological ef...
|
WO/1995/001965A1 |
Novel 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein R1 and R2, which are the same or different, are hydrogen or a C1-6 alkyl radical; n is an integer from 2 to 6; A is a grouping such as aryl piperazino (II...
|
WO/1994/022841A1 |
There is provided a compound of general formula (I) wherein X and Y are each independently an oxygen or sulphur atom; E and G are each independently a nitrogen or carbon atom but E is not the same as G; Z is either substantially complete...
|
WO/1994/021616A1 |
Compounds having the formula (I), which is explained in detail in the description, may be prepared by conventional methods and used in standard galenic compositions for therapeutical purposes.
|
WO/1994/021261A1 |
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine and its pharmaceutically and veterinarily acceptable acid addition salts can be used to treat anxiety and anxiety disorders.
|
WO/1994/021260A1 |
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine and its pharmaceutically and veterinarily acceptable acid addition salts can be used to treat impaired memory and learning disorders.
|
WO/1994/020110A1 |
The use of an antiepileptic selected from carbamazepine and oxcarbazepine or pharmaceutically acceptable salts thereof for treating AIDS-related neural disorders is disclosed.
|
WO/1994/020103A1 |
The use of riluzole or pharmaceutically acceptable salts thereof for treating AIDS-related neural disorders is disclosed.
|
WO/1994/020108A1 |
The use of lamotrigine or pharmaceutically acceptable salts thereof for treating AIDS-related neural disorders is disclosed.
|
WO/1994/018229A1 |
Compounds of formula (I), wherein R1 represents H, NH2, C1-6 alkyl optionally substituted by phenyl or naphthyl, R6CONH, R7OCONH or R8NHCONH; R2 represents H or C1-6 alkyl optionally substituted by phenyl; R3 represents H, phenyl or C1-6...
|
WO/1994/014781A1 |
Described is the use, in the preparation of drugs with a PLA2-inhibiting action, of compounds of the formula (I) in which R1 is an amino, a C1-C6 alkylamino, a di(C1-C6 alkyl)amino or a hydroxy group; R2 and R3, which may be the same or ...
|
WO/1994/014780A1 |
The use of a compound which binds at the tetrahydrobiopterin site of NO synthase for the treatment of conditions where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase is di...
|
WO/1994/013296A1 |
Application of lamotrigine or its pharmaceutically acceptable salts in the treatment of neurological lesions related to traumatic injuries, especially spinal, cranial or cranial-spinal injuries.
|
WO/1994/013288A1 |
Application of riluzole or its pharmaceutically acceptable salts in the treatment of neurological lesions related to traumatic injuries, especially spinal, cranial or cranial-spinal injuries.
|
WO/1994/013298A1 |
Application of an anticonvulsant selected from carbamazepine and oxcabarzepine or pharmaceutically acceptable salts thereof in the treatment of neurological lesions related to traumatic injuries, especially spinal, cranial or cranial-spi...
|
WO/1994/004514A1 |
Herbicidal compouds, compositions containing them, and a method for controlling weeds by application of the compositions are disclosed. The herbicidal compounds are 2-[(4-heterocyclic-phenoxymethyl)phenoxy]-alkanoates of formula (I), in ...
|
WO/1993/025207A1 |
3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine and its pharmaceutically and veterinarily acceptable salts have activity in (a) preventing or reducing dependence on, and (b) preventing or reducing tolerance or reverse tolerance to, a d...
|